Health Care & Life Sciences » Biotechnology | BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
30,108.00
45,189.00
43,019.00
55,144.00
65,782.00
101,252
Depreciation, Depletion & Amortization
304.00
177.00
180.00
483.00
704.00
770
Other Funds
5,180.00
-
-
-
-
11,447
Funds from Operations
30,338.00
39,856.00
31,561.00
45,887.00
50,470.00
89,035
Changes in Working Capital
3,808.00
1,305.00
18,445.00
7,551.00
9,327.00
3,530
Net Operating Cash Flow
26,530.00
38,551.00
13,116.00
53,438.00
41,143.00
92,565
Capital Expenditures
30.00
106.00
5,122.00
5,277.00
328.00
Sale of Fixed Assets & Businesses
50.00
-
-
4.00
12.00
Purchase/Sale of Investments
3,644.00
39,875.00
11,420.00
28,546.00
64,326.00
Net Investing Cash Flow
3,467.00
39,980.00
16,542.00
23,273.00
64,642.00
Issuance/Reduction of Debt, Net
-
-
-
22,987.00
122.00
Net Financing Cash Flow
30,270.00
111,907.00
5,479.00
23,304.00
135,703.00
Net Change in Cash
273.00
33,376.00
24,179.00
6,861.00
29,918.00
Free Cash Flow
26,560.00
38,657.00
18,238.00
58,715.00
41,471.00
Other Sources
157.00
1.00
-
-
-
Change in Capital Stock
25,090.00
111,907.00
5,479.00
317.00
135,581.00

About BioCryst Pharmaceuticals

View Profile
Address
4505 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.biocryst.com
Updated 07/08/2019
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.